Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug,... see more

GREY:ATBPF - Post Discussion

Antibe Therapeutics Inc(Pre-Merger) > Colchicine vs. Aspirin vs. Aspirin (with H2S)
View:
Post by MrMugsy on Jan 23, 2021 3:11pm

Colchicine vs. Aspirin vs. Aspirin (with H2S)

Now ... we can't talk about Aspririn (with H2S) yet.
We see some comparision for the first two (note - small population for Aspirin).
It sure shows why studies on Aspirin (with H2S) would be warranted.
Also, with new variants of COVID out there, finding the best therapeutics will likely be critical as other variants show up and as other viruses emerge.  

Just thinking.


-----

Aspirin:

The researchers examined the records of 412 adults with COVID-19 who were admitted to hospitals across the United States between March and July.  Slightly more than 23 percent of the people who were studied were given a daily low dose of aspirin within 24 hours of their admission to the hospital or in the 7 days prior to their admission.  The researchers reported that people taking aspirin were 44 percent less likely to be put on a ventilator and 43 percent less likely to be admitted to the intensive care unit (ICU).

https://www.healthline.com/health-news/aspirin-may-help-prevent-serious-covid-19-complications-heres-why

-----

Colchicine:

The ColCorona study involved 4,159 patients whose diagnosis of COVID-19 had been proven by a nasopharyngeal test (PCR).
Analysis of the study found that colchicine resulted in reductions in hospitalizations by 25 per cent, the need for mechanical ventilation by 50 per cent, and deaths by 44 per cent.

https://montreal.ctvnews.ca/quebec-researchers-say-they-have-found-an-effective-drug-to-fight-covid-19-1.5279310
Comment by Seemyvest on Jan 23, 2021 6:24pm
I don't understand why they can't talk about testing that they are doing with Covid . I guess it would not be material until it was completed but why not outline it in the recent overview or be open about what it is.  I just don't see the purpose of keeping it under wraps. 
Comment by MrMugsy on Jan 23, 2021 7:29pm
The only thing that makes sense to me is ... they are working with someone else and have signed an NDA ??????
Comment by Seemyvest on Jan 23, 2021 7:58pm
Okay, thank you. That does make sense.  I could not figure out why it would have them both smiling in the last fireside. But not mention anything about it at all. Thanks Mugsy
Comment by MrMugsy on Jan 24, 2021 12:59am
You are welcome Seemyvest. Hope they can give us many updates in the coming weeks and months ahead.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities